Overview

Olaparib was the first PARP inhibitor to reach the clinic, exploiting synthetic lethality in tumors that already carry a homologous-recombination repair defect, most classically BRCA1/2 mutations. By blocking PARP-mediated single-strand break repair, it forces cancer cells into a repair pathway they cannot complete, triggering catastrophic genomic instability. The 150 mg tablet is a mainstay SKU whose global regulatory footprint makes it a priority line for compliant B2B supply, and its oral schedule supports long-term outpatient maintenance therapy. The tablet avoids the infusion burden of cytotoxic regimens and fits multi-month maintenance programs that depend on uninterrupted outpatient supply.

How It Works

PARP enzymes repair DNA single-strand breaks through base-excision repair. Olaparib binds PARP at the damaged site and traps it, preventing repair. In a BRCA-deficient cell the alternative homologous-recombination route is already lost, so unrepaired damage accumulates and the cell dies. This selectivity spares most normal tissue, which retains intact repair capacity, and it underpins the favourable therapeutic index that has enabled prolonged administration in adjuvant and maintenance settings. Trapped PARP complexes collapse replication forks, and without homologous repair the cell cannot resolve the ensuing double-strand breaks, committing it to death.

Indications

Olaparib is used in BRCA-mutated ovarian cancer as maintenance therapy, in HER2-negative metastatic breast cancer with a germline BRCA mutation, and in metastatic castration-resistant prostate cancer with homologous-recombination repair alterations. Use is anchored to confirmed genetic status, and pancreatic cancer maintenance represents a further approved setting in several regions, broadening the addressable patient pool. Earlier-stage and adjuvant applications are being explored where germline defects are found, which would extend therapy duration and recurring procurement needs for distributors.

Dosage & Administration

The tablet regimen commonly uses 300 mg twice daily, built from 150 mg tablets, with hematologic monitoring and dose adjustments per label. Food effect is minimal, supporting outpatient adherence, and nausea is managed proactively during the early weeks of treatment.

Storage & Sourcing

Tablets ship in sealed blister packaging with controlled-temperature secondary cartons. GIVE LIFE TIME International supplies GMP documentation, batch release data, and export licenses suited to regulated markets.

FAQ

Q: What is synthetic lethality in PARP inhibition? A: It describes the tumor-specific death caused when PARP blockade meets an already defective BRCA repair pathway.

Q: Which patients qualify for olaparib? A: Those with BRCA or homologous-recombination repair alterations across ovarian, breast, pancreatic, and prostate settings.

Q: What documents support compliant import? A: GMP certificates, batch release testing, and the relevant marketing authorization or import permit per destination.